Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL17603642 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL1270317 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL7066091 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL14485682 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL8679969 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| (D)-Serine SCHEMBL2029988 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL9448210 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL27471642 | 0.95 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL1579756 | 0.91 | SLC7A5 (0.46) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| Serine SCHEMBL18427842 | 0.91 | SLC7A5 (0.46) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141786-A2 | MULTITARGET VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | claimed |
| US-10745449-B2 | UspA2 protein constructs and uses thereof | GLAXOSMITHKLINE (BE) | 2020-08-18 | — | — | US | claimed |
| CN-111499701-A | USPA2 protein constructs and uses thereof | 葛兰素史密斯克莱生物公司 | 2020-08-07 | — | — | CN | claimed |
| EP-3110438-B1 | USPA2 PROTEIN CONSTRUCTS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-01-02 | — | — | EP | claimed |
| US-20180354996-A1 | USPA2 PROTEIN CONSTRUCTS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-12-13 | — | — | US | claimed |
| CN-108467856-A | A kind of phosphorylated protein kinase SAPK10 mutant and its method | 中国水稻研究所 | 2018-08-31 | — | — | CN | claimed |
| EP-3110438-A1 | USPA2 PROTEIN CONSTRUCTS AND USES THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2017-01-04 | — | — | EP | claimed |
| CN-106061995-A | Uspa2 protein constructs and uses thereof | 葛兰素史密斯克莱生物公司 | 2016-10-26 | — | — | CN | claimed |
| WO-2015125118-A1 | USPA2 PROTEIN CONSTRUCTS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2015-08-27 | — | — | WO | claimed |
| CN-102631663-B | Compound amino acid composition and preparation for treatment of male sterility, impotence and premature ejaculation | ZHANG FENGFAN | 2014-08-20 | — | — | CN | claimed |
| US-20040091878-A1 | Zinc finger domain recognition code and uses thereof | SYNGENTA PARTICIPATIONS AG (CH) | 2004-05-13 | — | — | US | claimed |
| US-20030082561-A1 | Zinc finger domain recognition code and uses thereof | SYNGENTA PARTICIPATIONS AG (CH) | 2003-05-01 | — | — | US | claimed |
| EP-1303608-A2 | ZINC FINGER DOMAIN RECOGNITION CODE AND USES THEREOF | Syngenta Participations AG (CH) | 2003-04-23 | — | — | EP | claimed |
| WO-2002008286-A2 | ZINC FINGER DOMAIN RECOGNITION CODE AND USES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2002-01-31 | — | — | WO | claimed |
| CN-115135669-B | Modified Fc region | 硕腾服务有限责任公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-120137941-A | High-precision SpCas9 (S777A) variant and application thereof | 广东轻工职业技术学院 | 2025-06-13 | — | — | CN | disclosed |
| CN-118725323-A | Preparation method and application of silk fabric ultraviolet-proof material MOF-818 | 甘肃省文物考古研究所 | 2024-10-01 | — | — | CN | disclosed |
| WO-1991019505-A1 | MODIFIED HUMAN HEMOGLOBIN, BLOOD SUBSTITUTES CONTAINING THE SAME, AND VECTORS FOR EXPRESSING THE MODIFIED HEMOGLOBIN | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0355460-A2 | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization | AMERICAN CYANAMID COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
| US-4863727-A | ANTICARCINOGENIC AGENTS | CETUS CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091878-A1 | Zinc finger domain recognition code and uses thereof | ZFP3, CNBP, ZC3HAV1 | SLC7A5 1130/4885SLC1A1 2026/4885SLC1A3 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.